NasasBiotech had developed a novel extracellular vesicle (EV) isolation technology called ExoGAG. As we were interested in simple and fast technologies suitable for biomarker discovery, we tested the ExoGAG with our EV-specific technologies on urine samples in comparison to standard isolation technologies in the field. Finally, we reported the results to NasasBiotech. The project was mutually beneficial as NasasBiotech received important feedback and we gained forefront experience about this emerging fast technology.